1606 Corp. Target for Strategic Investment Adnexus Biotechnologies Merges With Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments
SEATTLE, WA / ACCESSWIRE / November 12, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606"), a leader in AI technology, acquisition target Adnexus Biotechnologies Inc. is delighted to reveal the completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise. The combination of resources...
Read more








